{"organizations": [], "uuid": "e00cb6848758ad3c0615dd1c0218b15376ae1a3a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180411.html", "section_title": "Archive News &amp; Video for Wednesday, 11 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-reata-provides-update-on-phase-2-p/brief-reata-provides-update-on-phase-2-portion-of-cardinal-study-of-bardoxolone-methyl-in-patients-with-alport-syndrome-idUSASC09VLI", "country": "US", "domain_rank": 408, "title": "BRIEF-Reata Provides Update On Phase 2 Portion Of Cardinal Study Of Bardoxolone Methyl In Patients With Alport Syndrome", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.481, "site_type": "news", "published": "2018-04-12T04:59:00.000+03:00", "replies_count": 0, "uuid": "e00cb6848758ad3c0615dd1c0218b15376ae1a3a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-reata-provides-update-on-phase-2-p/brief-reata-provides-update-on-phase-2-portion-of-cardinal-study-of-bardoxolone-methyl-in-patients-with-alport-syndrome-idUSASC09VLI", "ord_in_thread": 0, "title": "BRIEF-Reata Provides Update On Phase 2 Portion Of Cardinal Study Of Bardoxolone Methyl In Patients With Alport Syndrome", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "reata pharmaceuticals inc", "sentiment": "negative"}, {"name": "portion of cardinal study of bardoxolone methyl", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 11 (Reuters) - Reata Pharmaceuticals Inc:\n* REATA PROVIDES UPDATE ON THE PHASE 2 PORTION OF THE CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME\n* IN STUDY, BARDOXOLONE TREATMENT PRODUCED “SIGNIFICANT” INCREASE IN KIDNEY FUNCTION MAINTAINED THROUGH WEEK 36\n* BARDOXOLONE CONTINUES TO BE WELL-TOLERATED IN ALPORT SYNDROME PATIENTS\n* ADVERSE EVENTS HAVE BEEN GENERALLY MILD TO MODERATE IN SEVERITY, NO DRUG-RELATED SERIOUS ADVERSE EVENTS BEEN REPORTED IN TRIAL Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-12T04:59:00.000+03:00", "crawled": "2018-04-12T13:53:20.001+03:00", "highlightTitle": ""}